Durham, NCNCT05879367Now EnrollingIRB Ready

Glioblastoma, IDH-wildtype Clinical Trial in Durham, NC

Access cutting-edge glioblastoma, idh-wildtype treatment through this clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by Orbus Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access glioblastoma, idh-wildtype specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related glioblastoma, idh-wildtype treatment provided free

Apply for This Durham Location

Check if you qualify for this glioblastoma, idh-wildtype clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This Glioblastoma, IDH-wildtype Study in Durham

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

Sponsor: Orbus Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021 tumor classification.
Completed external beam radiation therapy per standard of care.
Patients with GBM: Must have received at least 80% of planned daily doses of TMZ during chemoradiation. Patients with astrocytoma: Must have tolerated adjuvant TMZ treatment through at least 2 and not more than 4 cycles.
Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.
Willing to abstain from intercourse or use acceptable contraceptive methods.
If taking corticosteroids, must be on a stable or decreasing dose.

Exclusion Criteria

Recent history of recurrent or metastatic cancer that could confound response assessments
Prior systemic chemotherapy other than temozolomide during external beam radiation therapy (for patients with GBM) or adjuvant temozolomide through up to 4 pre-study cycles (for patients with astrocytoma).
Prior Optune treatment.
Active infection or serious intercurrent medical illness.
Poorly controlled seizures.
Significant cardiac disease within 6 months of enrollment.
Poorly controlled diabetes.
Use of another investigational agent within 30 days of enrollment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT05879367) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma, IDH-wildtype Treatment Options in Durham, NC

If you're searching for glioblastoma, idh-wildtype treatment options in Durham, NC, this clinical trial (NCT05879367) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma, idh-wildtype specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma, idh-wildtype clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Durham, NC

See all brain cancer clinical trials recruiting in Durham — not just this study.

Browse Brain Cancer Trials in Durham →

Browse More Trials by Condition

Brain Cancer TrialsPulmonary Embolism TrialsAnkylosing Spondylitis TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC